Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb 16;102(4):629-38.
doi: 10.1038/sj.bjc.6605527. Epub 2010 Jan 26.

Treatment options for small cell lung cancer - do we have more choice?

M Puglisi  1 , S Dolly, A Faria, J S Myerson, S Popat, M E R O'Brien
Affiliations
Review

Treatment options for small cell lung cancer - do we have more choice?

M Puglisi et al. Br J Cancer. .

Abstract

Small cell lung cancer (SCLC) is a significant health problem worldwide because of its high propensity for relapse. This review discusses existing and future therapies for the treatment of SCLC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival rates of patients with LD-SCLC pre-2000: 5-year survival 13.9% vs 6.1% 2-year survival 17% vs 27%. (Unpublished data from the Royal Marsden Hospital, UK.)
See this image and copyright information in PMC

References

    1. Amarasena IU, Walters JA, Wood-Baker R, Fong K (2008) Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 4: CD006849 - PubMed
    1. Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y (2002) Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 93: 591–597 - PMC - PubMed
    1. Ardizzoni A (2004) Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist 9(Suppl 6): 4–13 - PubMed
    1. Argiris A, Murren JR (2001) Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 7: 437–447 - PubMed
    1. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25: 4278–4284 - PubMed

Substances